{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:08:20Z","timestamp":1786975700980,"version":"build-2736575974"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Limited evidence is available on the comparative effectiveness of empagliflozin vs alternative second-line glucose-lowering agents in patients with type 2 diabetes (T2D) receiving routine care who have a broad spectrum of cardiorenal risk.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the association of empagliflozin with cardiovascular outcomes relative to liraglutide and sitagliptin, stratified by age, sex, baseline atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective comparative effectiveness cohort study used deidentified Medicare claims data from August 1, 2014, to September 30, 2018, with follow-up from drug initiation until treatment changes, death, or gap in Medicare enrollment (&amp;gt;30 days). Data analysis was performed from October 1, 2021, to April 30, 2022. Medicare fee-for-service beneficiaries older than 65 years with T2D were included. A total of 45 788 patients (22\u202f894 propensity score\u2013matched pairs initiating treatment with either empagliflozin or liraglutide) were included in cohort 1, and 45 624 patients (22\u202f812 propensity score\u2013matched pairs initiating treatment with either empagliflozin or sitagliptin) were included in cohort 2.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Empagliflozin vs liraglutide (cohort 1) or empagliflozin vs sitagliptin (cohort 2).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary outcomes were (1) modified major adverse cardiovascular events (MACEs), including a composite of myocardial infarction, stroke, and all-cause mortality, and (2) hospitalization for heart failure (HHF). Hazard ratios (HRs) and rate differences (RDs) per 1000 person-years were estimated, adjusting for 143 baseline covariates using 1:1 propensity score matching.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 45 788 patients in cohort 1, the mean (SD) age was 71.9 (5.1) years; 23 396 patients (51.1%) were female, 22 392 (48.9%) were male, and 38 049 (83.1%) were White. Among 45 624 patients in cohort 2, the mean (SD) age was 72.1 (5.1) years; 21 418 patients (46.9%) were female, 24 206 (53.1%) were male, and 37 814 (82.9%) were White. Relative to patients initiating liraglutide, those initiating empagliflozin had a similar risk of the modified MACE outcome (HR, 0.90; 95% CI, 0.79-1.03) and a reduced risk of HHF (HR, 0.66; 95% CI, 0.52-0.82). Across subgroups, empagliflozin was associated with a lower risk of the modified MACE outcome in patients with a history of ASCVD (HR, 0.83; 95% CI, 0.71-0.98) and HF (HR, 0.77; 95% CI, 0.60-1.00) compared with liraglutide, and potential heterogeneity in estimates was observed by sex (male: HR, 0.85 [95% CI, 0.71-1.01]; female: HR, 1.16 [95% CI, 0.94-1.42];\n P<\/jats:italic>\n \u2009=\u2009.02 for homogeneity). However, reductions in the risk of HHF were observed across most subgroups (eg, ASCVD: HR, 0.66 [95% CI, 0.51-0.85]; HF: HR, 0.66 [95% CI, 0.49-0.88]). Compared with sitagliptin, empagliflozin was associated with reduced risks of the modified MACE outcome (HR, 0.68; 95% CI, 0.60-0.77) and HHF (HR, 0.45; 95% CI, 0.36-0.56), which were consistent across all subgroups. Absolute benefits of empagliflozin vs sitagliptin were larger in patients with a history of ASCVD (modified MACE: RD, \u221217.6 [95% CI, \u221224.9 to \u221210.4]; HHF: RD, \u221216.7 [95% CI, \u221221.7 to \u221211.9]), HF (modified MACE: RD, \u221241.1 [95% CI, \u221259.9 to \u221222.6]; HHF: RD, \u221250.4 [95% CI, \u221267.5 to \u221233.9]), or CKD (modified MACE: RD, \u221226.7 [95% CI, \u221241.3 to \u221212.3]; HHF: RD, \u221231.9 [95% CI, \u221243.5 to \u221220.8]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this comparative effectiveness study of older adults, empagliflozin was associated with a lower risk of HHF (relative to both liraglutide and sitagliptin) and the modified MACE outcome (relative to sitagliptin), with larger absolute benefits in patients with established cardiorenal diseases. These findings suggest that older adults with T2D might benefit more from empagliflozin vs liraglutide or sitagliptin with respect to the risk of HHF; with respect to the risk of MACEs, empagliflozin might be preferable to liraglutide only in patients with cardiovascular disease history and to sitagliptin across all patient subgroups.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.37606","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T11:03:28Z","timestamp":1666263808000},"page":"e2237606","source":"Crossref","is-referenced-by-count":29,"title":["Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics"],"prefix":"10.1001","volume":"5","author":[{"given":"Phyo T.","family":"Htoo","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Tesfaye","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Wexler","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Everett","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoung C.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Najafzadeh","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette","family":"Koeneman","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Lilly Deutschland, Aalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soulmaz Fazeli","family":"Farsani","sequence":"additional","affiliation":[{"name":"Global Epidemiology, Boehringer Ingelheim International, Ingelheim am Rheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"D\u00e9ruaz-Luyet","sequence":"additional","affiliation":[{"name":"Global Epidemiology, Boehringer Ingelheim International, Ingelheim am Rheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Paik","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Patorno","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"issue":"1","key":"zoi221066r1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","article-title":"Association of cardiometabolic multimorbidity with mortality.","volume":"314","author":"Di Angelantonio","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"zoi221066r2","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"zoi221066r3","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20132022.","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"zoi221066r4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-020-01133-1","article-title":"Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.","volume":"19","author":"D\u2019Andrea","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"10166","key":"zoi221066r5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"zoi221066r6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi221066r7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/ageing\/afz096","article-title":"Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME trial.","volume":"48","author":"Monteiro","year":"2019","journal-title":"Age Ageing"},{"issue":"6","key":"zoi221066r8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.7326\/M18-1569","article-title":"Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial.","volume":"170","author":"Gilbert","year":"2019","journal-title":"Ann Intern Med"},{"issue":"11","key":"zoi221066r9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019356","article-title":"Cardiovascular events, acute hospitalizations, and mortality in patients with type 2 diabetes mellitus who initiate empagliflozin versus liraglutide: a comparative effectiveness study.","volume":"10","author":"Thomsen","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"zoi221066r10","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/dom.2019.21.issue-6","article-title":"Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.","volume":"21","author":"Boye","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"zoi221066r11","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2337\/dc19-1943","article-title":"Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018.","volume":"43","author":"Dave","year":"2020","journal-title":"Diabetes Care"},{"key":"zoi221066r12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"issue":"3","key":"zoi221066r13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi221066r14","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1161\/STROKEAHA.114.006316","article-title":"Validity of hospital discharge diagnosis codes for stroke: the Atherosclerosis Risk in Communities Study.","volume":"45","author":"Jones","year":"2014","journal-title":"Stroke"},{"issue":"1","key":"zoi221066r15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2004.02.013","article-title":"Accuracy of Medicare claims\u2013based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records.","volume":"148","author":"Kiyota","year":"2004","journal-title":"Am Heart J"},{"issue":"3","key":"zoi221066r16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092286","article-title":"Validity of myocardial infarction diagnoses in administrative databases: a systematic review.","volume":"9","author":"McCormick","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"zoi221066r17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/01.mlr.0000160417.39497.a9","article-title":"Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors.","volume":"43","author":"Birman-Deych","year":"2005","journal-title":"Med Care"},{"issue":"1","key":"zoi221066r18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cardfail.2015.07.013","article-title":"Identification of heart failure events in Medicare claims: the Atherosclerosis Risk in Communities (ARIC) study.","volume":"22","author":"Kucharska-Newton","year":"2016","journal-title":"J Card Fail"},{"issue":"7","key":"zoi221066r20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores.","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"zoi221066r21","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/gerona\/glz224","article-title":"Measuring frailty in administrative claims data: comparative performance of four claims-based frailty measures in the U.S. Medicare data.","volume":"75","author":"Kim","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"zoi221066r22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects.","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"9","key":"zoi221066r23","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/aje\/kwy078","article-title":"Implications of the propensity score matching paradox in pharmacoepidemiology.","volume":"187","author":"Ripollone","year":"2018","journal-title":"Am J Epidemiol"},{"issue":"25","key":"zoi221066r24","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"10","key":"zoi221066r25","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects.","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med"},{"issue":"3","key":"zoi221066r26","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/aje\/kwq099","article-title":"A simple approach to the estimation of incidence rate difference.","volume":"172","author":"Xu","year":"2010","journal-title":"Am J Epidemiol"},{"issue":"3","key":"zoi221066r27","first-page":"141","article-title":"An empirical transition matrix for non-homogeneous Markov chains based on censored observations.","volume":"5","author":"Aalen","year":"1978","journal-title":"Scandinavian Journal of Statistics"},{"issue":"5","key":"zoi221066r28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/(ISSN)1099-1557","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.","volume":"15","author":"Schneeweiss","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"zoi221066r29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/cpt.v99.3","article-title":"Transparency and reproducibility of observational cohort studies using large healthcare databases.","volume":"99","author":"Wang","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"15","key":"zoi221066r30","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1001\/archinte.168.15.1699","article-title":"The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program.","volume":"168","author":"Gerstein","year":"2008","journal-title":"Arch Intern Med"},{"issue":"4","key":"zoi221066r31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi221066r32","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes.","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi221066r33","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs.","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"4","key":"zoi221066r35","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/dom.2018.20.issue-4","article-title":"Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records.","volume":"20","author":"Patorno","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"zoi221066r36","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.2337\/dc19-0069","article-title":"Using real-world data to predict findings of an ongoing phase IV cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride.","volume":"42","author":"Patorno","year":"2019","journal-title":"Diabetes Care"},{"issue":"10","key":"zoi221066r37","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1161\/CIRCULATIONAHA.120.051718","article-title":"Emulating randomized clinical trials with nonrandomized real-world evidence studies: first results from the RCT DUPLICATE Initiative.","volume":"143","author":"Franklin","year":"2021","journal-title":"Circulation"},{"key":"zoi221066r34","author":"Lash","year":"2020"},{"key":"zoi221066r19","unstructured":"Research Data Assistance Center. Death information in the research identifiable Medicare data. Research Data Assistance Center. July 11, 2018. Accessed October 2020. https:\/\/resdac.org\/articles\/death-information-research-identifiable-medicare-data"},{"key":"zoi221066r38","unstructured":"Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Centers for Disease Control and Prevention, US Department of Health and Human Services. June 2008. Accessed October 2020. https:\/\/stacks.cdc.gov\/view\/cdc\/5613\/cdc_5613_DS1.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797498\/htoo_2022_oi_221066_1665581893.99639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T11:03:33Z","timestamp":1666263813000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.37606","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]}}}